While gene therapy for AD remains in its developmental infancy, rigorous mechanistic insight and technological innovation are poised to transform neurotrophin-based interventions into viable clinical modalities in the pursuit of halting or reversing neurodegenerative decline. The gene discussed is BDNF; the disease is Alzheimer disease.